Allergic Rhinitis Market Size

Global Allergic Rhinitis Market Overview

Allergic Rhinitis Market Valued at USD 11.9 billion in 2023, projected to grow from USD 12.3 billion in 2024 to USD 19.57 billion by 2032, exhibiting a CAGR of 3.70% during the forecast period (2024 - 2032). Rising frequency of cervical spondylosis among corporate workers and the increasing occurrences of cervical injuries in vehicle accidents are the key market drivers enhancing the market growth.

Allergic Rhinitis Market Trends

Increase spending towards healthcare disease to boost market growth

Over the past few decades, it has been noted that spending on health diseases has increased. This raises the awareness that different therapies are available to treat different ailments. This increase in healthcare costs has increased the demand for high-quality medicines and the fastest diagnostic methods for rapid recovery from any illness. For this reason, the demand for allergic rhinitis medicines in the market will grow, which will help drive the growth of the market in the coming years. Other important factors driving the growth of the allergic rhinitis medicines market are medical expenses , high demand for new technology investment, increasing diagnostic methods to treat various diseases, and increasing awareness of treatment availability during the forecast period.

Increasing availability of allergen immunotherapy solutions is one of the factors expected to drive market growth during the forecast period. For instance, in June 2021, Stallergenes Greer, one of his world leaders in allergy immunotherapy, launched a subcutaneous allergen immunotherapy (SCIT) solution for various allergies such as rhinitis, conjunctivitis, rhinoconjunctivitis and asthma. Alusta is now available in Spain and Italy. Available.

The factors driving the allergic rhinitis treatment market are the prevalence of respiratory diseases due to high levels of air pollution and climate change. For instance, in March 2020, the ScienceDirect website published a study showing that people with allergic rhinitis who are exposed to pollution and climate change have significant health consequences. Increased symptoms of allergic rhinitis are observed by an induced inflammatory response and recruitment of inflammatory cells such as cytokines and interleukins.Other factors contributing to the growth of the global allergic rhinitis treatment market are increasing incidence of allergic rhinitis, increasing environmental pollution, increasing funding for research and development, demand for early treatment due to efficiency of diagnostic tools, and related treatment efficacy. Rhinitis with allergic rhinitis. However, the factors limiting the growth of the global allergic rhinitis treatment market are the increasing urge of patients to self-medicate with over-the-counter medications and side effects associated with allergic rhinitis treatment.

Allergic Rhinitis Market Segment Insights

Allergic Rhinitis Type Insights

The allergic rhinitis market segmentation, based on type, includes seasonal allergic rhinitis, perennial allergic rhinitis, and occupational allergic rhinitis. The seasonal Allergic Rhinitis segment held the majority share in 2021 in respect to the allergic rhinitis market revenue. This is primarily owing to the rising awareness about allergic rhinitis and high usage of tobaccoacross the globe. Pollen is the most common allergen in seasonal allergic rhinitis. Mold, animal dander, and dust are the other substances that can cause allergic rhinitis.

November 2021: Revolo Biotherapeutics, a biotherapeutics company, started a phase II clinical trial for IRL201104, a novel immunomodulatory peptide drug indicated for seasonal allergic rhinitis. The study is expected to be completed in February 2023.

Allergic Rhinitis Treatment Insights

The market segments of allergic rhinitis, based on treatment, includes Antihistamines, Corticosteroids, Immunotherapy, Decongestants and others. The Antihistamines segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Antihistamines drugs help in the treatment of allergic rhinitis and other allergies. People take antihistamines as inexpensive, generic, over-the-counter drugs that can give relief from nasal congestion, and sneezing. Hence, rising applications of Antihistamines treatment for Allergic Rhinitis positively impacts the market growth.

Allergic Rhinitis Route of Administration Insights

The market of allergic rhinitis has been bifurcated by Route of Administration into Oral, and Nasal & Others. The nasal & other route of administration segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The market is estimated to grow owing to the quality of drugs and nasal sprays manufactured by manufacturers for the effective treatment of allergic rhinitis.

May 2021: Glenmark Pharma has launched its nasal spray Ryaltris, used for the treatment of moderate to severe allergic rhinitis, in India. This initiativel has further broadened the growth opportunity for the Allergic Rhinitis industry.

Figure 2: Allergic rhinitis market, by Route of Administration, 2023 & 2032(USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Allergic Rhinitis Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Allergic Rhinitis market accounted for USD 6.0048 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to the large amount of R&D expenditure for the development of allergy treatment across the region.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: ALLERGIC RHINITIS MARKET SHARE BY REGION 2023(%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe market of allergic rhinitis accounts for the one of the largest market share due to the established healthcare system, high medical expenditure, access to advanced treatment solutions, demand for preventive care by diagnostic examinations, research funding for early treatment options, and higher awareness of allergic rhinitis. Further, the Germany market of allergic rhinitis held the largest market share, and the UK market of allergic rhinitis was the fastest growing market in the European region

The Asia-Pacific market of allergic rhinitis is expected to grow at the fastest CAGR from 2024 to 2032. This is due to the rising healthcare expenditure and high disposable income. High demand of advance technology and high prevalence of respiratory disease are fuelling the market growth of Allergic Rhinitis Drugs in the region. Moreover, China Allergic market of allergic rhinitis held the largest market share, and the India market of allergic rhinitis was the fastest growing market in the Asia-Pacific region.

Allergic Rhinitis Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the Allergic Rhinitis market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Allergic Rhinitis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global Allergic Rhinitis industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Allergic Rhinitis industry has provided medicine with some of the most significant benefits. The Allergic Rhinitis market major player such as AstraZeneca, GlaxoSmithKline plc, Johnson & Johnson Services, Bayer AG, ALK-Abelló A/S, Glenmark and others are working to expand the market demand by investing in research and development activities.

ALK-Abelló A/S is a Denmark-based pharmaceutical company which specializes in the development and manufacture of allergy immunotherapy products for the prevention and treatment of allergy. In March 2021, ALK-Abelló A/S, a pharmaceutical company, announced its submission of a registration application in China, under National Medical Products Administration (NMPA), Chinese agency for regulating drugs and medical devices, for its ACARIZAX, a house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet. In June 2019, ALK announced the successful marketing of sublingual allergy immunotherapy (SLIT) tablet in 17 European countries.

Also, Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India. Its portfolio of differentiated medicines in respiratory, dermatology and oncology is acclaimed as breakthrough solutions for a wide range of diseases.  In February 2020, Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, and Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals, a global innovative pharmaceutical company, announced the signing of an exclusive US license agreement to commercialise Ryaltris, an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR)..

Key Companies in the Allergic Rhinitis market includes

• AstraZeneca


• GlaxoSmithKline plc


• Johnson & Johnson Services


• Glenmark Pharmaceutical Limited


• Bayer AG


• Sanofi


• Boehringer Ingelheim


• Merck & Co.


• ALK-Abelló A/S


• Novartis AG


• Meda Pharmaceuticals

Allergic Rhinitis Industry Developments

November 2022: a clinical trial of Tree MATA MPL or Tree MATA immunotherapy for allergic rhinitis and type I hypersensitivity I was terminated due to poor enrollment of subjects. The clinical trial was sponsored by Allergy Therapeutics, a manufacturer of subcutaneous and sublingual immunotherapy treatments.

November 2020: In November 2020, Dr Reddys Laboratories announced that it has entered into a definitive agreement with Glenmark Pharmaceuticals to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine).

April 2021: ALK announced the successful approval from FDA regarding short ragweed pollen allergen extract for the treatment of patients aged 5 to 65 years with short ragweed pollen-induced allergic rhinitis.

Allergic Rhinitis Market Segmentation

Allergic Rhinitis Type Outlook

• Seasonal Allergic Rhinitis


• Perennial Allergic Rhinitis


• Occupational Allergic Rhinitis

Allergic Rhinitis Treatment Outlook

• Antihistamines


• Corticosteroids


• Immunotherapy


• Decongestants and others

Allergic Rhinitis Route of Administration Outlook

• Oral


• Nasal and others

Allergic Rhinitis Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America